- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Aquaporin A/S - rights issue, admission to trading and official listing of subscription rights | 76 | GlobeNewswire | Subscription rights in Aquaporin A/S will be admitted to trading and official listing on Nasdaq Copenhagen as of 5 January 2026. As of the same date, ISIN DK0061555109 (AQP) will be traded excl.... ► Artikel lesen | |
| Fr | Aquaporin A/S: Aquaporin updates on strategic review and sets mid-and long-term financial targets | 188 | PR Newswire | Company announcementNo. 21/2025Inside informationAquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694KONGENS LYNGBY, Denmark, Dec. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| Fr | Aquaporin A/S: Aquaporin initiates rights issue | 216 | PR Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR... ► Artikel lesen | |
| AQUAPORIN Aktie jetzt für 0€ handeln | |||||
| Fr | Aquaporin A/S: Aquaporin updates on strategic review and sets mid-and long-term financial targets | 257 | PR Newswire | Company announcementNo. 21/2025Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| Fr | AQUAPORIN A/S: Aquaporin updates on strategic review and sets mid- and long-term financial targets | 2 | Cision News | ||
| 01.12. | Business transacted at the extraordinary general meeting of Aquaporin A/S | 268 | PR Newswire | Company announcementNo. 20/2025Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany reg. no.: DK28315694KONGENS LYNGBY, Denmark, Dec. 1, 2025 /PRNewswire/ -- Aquaporin A/S... ► Artikel lesen | |
| 01.12. | Aquaporin A/S: Business transacted at the extraordinary general meeting of Aquaporin A/S | 110 | GlobeNewswire (Europe) | Company announcement
No. 20/2025
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company reg. no.: DK28315694
Kongens Lyngby, Denmark, December 1, 2025 - Aquaporin A/S ("Aquaporin"... ► Artikel lesen | |
| 13.11. | Aquaporin A/S: Aquaporin Q3 2025 Trading Statement | 197 | PR Newswire | Company announcement
No. 19/2025
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 07.11. | Aquaporin A/S: Notice to convene an extraordinary general meeting | 387 | PR Newswire | Company announcement
No. 18/2025
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 07.11. | Aquaporin A/S: Update on strategic review and intention to strengthen financial position | 338 | PR Newswire | Company announcement
No. 17/2025Inside information
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS... ► Artikel lesen | |
| 21.08. | Aquaporin A/S: Aquaporin announces results for first half 2025 | 363 | PR Newswire | Company announcement No. 16/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngby aquaporin.com Company registration no.: DK28315694
KONGENS LYNGBY, Denmark, Aug. 21, 2025 /PRNewswire/... ► Artikel lesen | |
| 13.08. | AQUAPORIN A/S: Aquaporin to host half-year 2025 results webcast on August 21 | 3 | Cision News | ||
| 12.08. | Aquaporin Cuts FY Revenue Guidance, Initiates Strategic Review | 1 | RTTNews | ||
| 11.08. | Aquaporin A/S: Aquaporin lowers revenue guidance for 2025, but maintains EBITDA guidance, and initiates strategic review | 1.114 | PR Newswire | Company announcementNo. 15/2025Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark, Aug.... ► Artikel lesen | |
| 05.08. | Aquaporin A/S: Aquaporin successfully achieves up to 20% energy savings at Kranji NEWater Factory | 351 | PR Newswire | KONGENS LYNGBY, Denmark, Aug. 5, 2025 /PRNewswire/ -- Aquaporin has successfully completed the Living Lab Project to develop the world's first biomimetic low-energy Aquaporin Inside® CLEAR... ► Artikel lesen | |
| 08.07. | AQUAPORIN A/S: Reporting of transactions in financial instruments linked to Aquaporin's shares by persons discharging managerial responsibilities | 2 | Cision News | ||
| 07.07. | AQUAPORIN A/S: Aquaporin issues warrants under a new warrant program | 2 | Cision News | ||
| 12.06. | Aquaporin A/S: Aquaporin appoints Chief Executive Officer | 460 | PR Newswire | Company announcementNo. 09/2025
Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark... ► Artikel lesen | |
| 21.05. | Aquaporin A/S: Aquaporin Q1 2025 Trading Statement - maintains full-year financial guidance for 2025 | 366 | PR Newswire | Company announcementNo. 08/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark , May 21, 2025 /PRNewswire/... ► Artikel lesen | |
| 11.04. | Aquaporin A/S - Admittance to trading and official listing of new shares due to exercise of warrants | 215 | GlobeNewswire | The share capital of Aquaporin A/S has been increased. The admittance of trading and official listing of new shares will take effect as per 14 April 2025 in the ISIN below.
ISIN:
DK0061555109
Name:
Aquaporin
Volume... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 72,20 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,340 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,900 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 84,35 | 0,00 % | Kymera Therapeutics stock price target raised to $103 from $70 at RBC Capital | ||
| PRAXIS PRECISION MEDICINES | 280,40 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,400 | 0,00 % | Cathie Wood's ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals | ||
| EDGEWISE THERAPEUTICS | 20,940 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| IMMUNOME | 22,030 | 0,00 % | Hedge Fund and Insider Trading News: Michael Hintze, Xavier Majic, Stanley Druckenmiller, Warren Buffett, Bill Ackman, Bridgewater Associates, Citadel Investment Group, Infini Capital, Immunome Inc (IMNM), White Mountains Insurance Group Ltd (WTM), and Mo | ||
| IMMUNOVANT | 27,540 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| CG ONCOLOGY | 40,080 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates | Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 81,98 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| JYONG BIOTECH | 4,780 | 0,00 % | Jyong Biotech Ltd.: Jyong Biotech Responds to Share Price and Volume Movement | New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech") notes the recent fluctuation in its share price and the increased trading... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 63,35 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| VERA THERAPEUTICS | 53,80 | 0,00 % | Vera Therapeutics stock price target raised to $66 by BofA Securities | ||
| BICARA THERAPEUTICS | 18,320 | 0,00 % | Mizuho initiates Bicara Therapeutics stock coverage with Neutral rating |
Das Unternehmen AQUAPORIN A/S kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -12,60 % bei einem Aktienkurs von 0,312 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AQUAPORIN A/S finden Sie auf Wallstreet Online.